CTAG1A Antibody

1. Twenty-eight out of 38 cancer specimens exhibited NY-ESO-1 protein expression, 2/38 showed a strong universal (4+) NY-ESO-1 staining, and 9/40 cancer lesions exhibited a strong (4+) staining for survivin. PMID:29058035
2. A significant association was found between AKAP4 gene expression and metastasis (P-value: 0.045), expression of the CTAG1B (NY-ESO-1) gene was not observed in our cases. PMID:29480665
3. In 22 melanoma patients with stage III lymph node metastasis, overall survival was significantly higher in the XAGE-1b and NY-ESO-1 double-negative group than in the other groups. PMID:28105694
4. The present results indicate the strong humoral immune response against NY-ESO-1 in natural human T-cell leukemia virus type 1 infection, irrespective of the clinical status. PMID:28716148
5. some autoantibodies, such as anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers. PMID:27140836
6. High NY-ESO-1 expression is associated with Lung Cancer. PMID:27793776
7. Results support the potential utility of NY-ESO-1, PRAME, and MAGEA4 as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas. PMID:27993576
8. Data suggest that only a small fraction of HLA-A*02:01- (HA)-binding ESO peptides are immunogenic, namely those that have high peptide-binding strength and peptide/HA complex stability. This study involved comparison of in silico-predicted and observed cytotoxic T-lymphocyte recognition of tumor antigen epitopes in melanoma patients and transgenic/knockout mice. (ESO = tumor antigen NY-ESO-1) PMID:28536262
9. These data demonstrate that MAGE-A1-, MAGE-A3-, and NY-ESO-1-specific T cells with antigen-specific cytotoxicity can be cultured from healthy donors and patient-derived cells making adoptive immunotherapy with these cytotoxic T lymphocyte feasible. PMID:28677424
10. Comparing the overall expression of CTAs, a decreased expression of all melanoma-associated antigens (MAGEs) post-treatment and a slightly increased expression of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) was visible. The simultaneous cytoplasmic and nuclear expression of pan-MAGE or MAGE-A3/A4 correlated with reduced treatment-failure-free-survival (TFFS). PMID:27466502
11. MAGE-A is more highly expressed than NY-ESO-1 in a majority of human malignancies PMID:27070449
12. These cells were used to target a human lung cancer line that expressed NY-ESO-1. PMID:26324743
13. regulation of NY-ESO-1 processing by the ubiquitin receptors Rpn10 and Rpn13 as a well as by the standard and immunoproteasome is governed by non-canonical ubiquitination on non-lysine sites. PMID:26903513
14. CTAs (MAGE-A4, NY-ESO-1, MAGE-A10) were more likely expressed in patients with squamous cell carcinoma of the lung and when CTAs combined with CD133, they can be better prognostic factors. PMID:26191258
15. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). PMID:25412843
16. High expression of NY-ESO-1 is associated with Triple-Negative Breast Cancer. PMID:26413775
17. NY-ESO-1 expression in melanoma was associated with tumor progression, including increased tumor thickness, and with reduced tumor infiltrating lymphocytes. PMID:25954764
18. NY-ESO-1 is expressed in esophageal adenocarcinomas, Barrett's metaplasia and normal tissues other than germ cells PMID:24744590
19. NY-ESO-1 cancer antigen expression has a role in immunotherapy in thyroid cancer PMID:24811699
20. primary autoantibodies against intracellular MM-specific tumor antigens SSX-2 and NY-ESO-1 are rare but functional in multiple myeloma patients after allogeneic stem cell transplantation PMID:25078248
21. We have also shown that NY-ESO-1 expression may lead to humoral immune response in patients with meningioma. PMID:24777967
22. NY-ESO-1 tetramer(+) cells were detected concomitantly with high proportions of Treg but were distinct from the latter and displayed characteristics of TH1 effectors. PMID:24777968
23. neck squamous cell carcinoma patients showing protein expression of MAGE-A family members or NY-ESO-1 represent a subgroup with an extraordinarily poor survival. PMID:24482145
24. Our observations indicate a tight link of NY-ESO-1 expression to ERG activation PMID:24789172
25. NY-ESO-1 and SP17 was not significantly associated with a specific histotype, but high-level GAGE expression was more frequent in squamous cell carcinoma. GAGE expression was demonstrated to be significantly higher in stage II-IIIa than stage I NSCLC. PMID:24103781
26. NY-ESO-1 appears to be a sensitive and a specific marker for myxoid and round cell liposarcoma among mesenchymal myxoid neoplasms. PMID:23599152
27. Positive results of immunohistostaining were obtained in 16 (35.6%), 7 (15.6%) and 36 (80.0%) samples using MAGE-C1, NY-ESO-1 and Sp17 antibodies, respectively PMID:23923079
28. study analyzed NY-ESO-1 expression in 222 melanoma specimens including 16 primary and 206 metastatic tumors; results support previous findings showing higher expression of NY-ESO-1 in metastatic (58/206) versus primary (0/16) tumors; results also show epithelioid subtype of melanoma has the highest incidence of NY-ESO-1 expression PMID:24290058
29. In two non epithelial cancers (glioma and mesothelioma), the epigenetic regulation of the NY-ESO-1 gene requires the sequential recruitment of the HDAC1-mSin3a-NCOR, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a complexes. PMID:23312906
30. Melanoma patients' humoral immune systems responded to NY-ESO-1 differently in each individual. PMID:23454162
31. CTAG1B mRNA and protein are overexpressed with high frequency in myxoid and round cell liposarcoma PMID:22936067
32. High CTAG1 expression and down-regulation of HLA class-I is associated with non-small cell lung cancer. PMID:23645764
33. NY-ESO-1 is strongly and diffusely expressed in a majority of synovial sarcomas, but only rarely in other mesenchymal lesions. Suggest roles in targeted therapy and differential diagnosis. PMID:22388761
34. The presence of circulating T cells responding to Melan-A or NY-ESO-1 had strong independent prognostic impact on survival in advanced melanoma. PMID:22529253
35. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. PMID:22323448
36. Polymeric structure and TLR4 may play important roles in rendering NY-ESO-1 immunogenic and thus serve as a potent molecular adjuvant. NY-ESO-1 thus represents the first example of a cancer/testis antigen PMID:21900253
37. Integrated NY-ESO-1 immune responses may have predictive value for ipilimumab treatment in patients with advanced metastatic melanoma. PMID:21933959
38. Primary tumors with and without lymph node metastases showed no significant differences in MAGE-A 3/4 (P=0.672) and NY-ESO-1 (P=0.444) expression PMID:21556122
39. LAGE-1a and NY-ESO-1 homology cannot be easily exploited in an anti-NY-ESO-1 vaccine given the low frequency of protein expression detected by IHC or serum analysis. PMID:21247062
40. Report immunohistochemical expression of NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma. PMID:20591578
41. Most melanoma patients with spontaneous NY-ESO-1-specific responses in this study exhibit spontaneous CD4-positive T cell responses to at least one of the three immunodominant LAGE-1 epitopes. PMID:21131422
42. A versatile prime-boost vaccine strategy allows the generation of powerful, high-avidity tumor-associated immunodominant NY-ESO-1-transgene specific CD8-positive cytotoxic T cell responses. PMID:20733200
43. tumor antigen NY-ESO-1 has a role in the immune responses to tumor and self-antigens PMID:20368442
44. ESO 9V peptide isoform is more efficient in inducing conjugate formation and cytolytic granule polarization than the ESO 9L isoform. PMID:20053942
45. MAGE-A3/6 and NY-ESO-1 were expressed in 50.0% (66/132) and 18.2% (24/132) of non-small-cell lung carcinomas, respectively. PMID:19795170
46. High NY-ESO-1 expression is associated with oral squamous cell carcinoma. PMID:20044626
47. Postvaccine T-cell clones are shown to recognize and lyse NY-ESO-1 expressing tumor cell lines in vitro. PMID:19728336
48. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. PMID:11782380
49. NY-ESO-1 is a marker that can be used to follow the early progression of testicular tumorigenesiswhen the tumors express a similar pattern to the cells of origin,although later tumors cease to express NY-ESO-1. PMID:12065688
50. abilities of human monocyte-derived DCs and DCs derived in vitro from CD34-positive stem cells to present NY-ESO-1 epitopes to MHC class I-restricted cytotoxic T cells PMID:12138174

Show More

Hide All

HGNC: 24198

UNIGENE: Hs.534310

KEGG: hsa:1485

STRING: 9606.ENSP00000332602

OMIM: 300156